| BSX |
Report |
Q2 organic sales growth |
IN-LINE |
pred ~5.6% vs. cons 5.3%. |
MEDIUM |
| BSX |
Report |
Q2 adjusted EPS |
BEAT |
pred ~$0.85 vs. cons $0.83. |
MEDIUM |
| BSX |
Report |
Q2 WATCHMAN organic sales growth |
MISS |
pred ~10.5% vs. cons 13.0%. |
MEDIUM |
| BSX |
Guide |
FY2026 organic sales growth |
UNCHANGED |
guide ~7.25% vs. cons 7.20% (FY2026). |
HIGH |
| BSX |
Guide |
FY2026 adjusted EPS |
UNCHANGED |
guide ~$3.38 vs. cons $3.38 (FY2026). |
HIGH |
| BSX |
Guide |
Q3 organic sales growth |
LOWER |
guide ~6.7% vs. cons 7.2% (Q3 2026). |
MEDIUM |
| BSX |
Guide |
Q3 adjusted EPS |
LOWER |
guide ~$0.84 vs. cons $0.85 (Q3 2026). |
MEDIUM |
| BSX |
Return |
Day-1 residual (stock − beta × S&P 500) |
+4.5% |
— |
MEDIUM |
| BSX |
Return |
5-day cumulative residual |
+2.0% (FADE) |
A ~$0.02 EPS beat versus $0.83 and maintained FY EPS midpoint of ~$3.38 versus $3.38 should initially relieve fears of another reset, but a softer Q3 organic-growth guide of ~6.7% versus 7.2% and WATCHMAN growth of ~10.5% versus 13.0% should pull 2026H2 and 2027 revenue estimates lower. |
MEDIUM |